Revelation Biosciences, Inc. (REVBW)
REVBWNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.00210000
0.0000 (0.00%) today
Pre-market, Nov 19, 9:55 AM ET
- Market cap
- $1,435
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.00210000 to $0.0398
- Average volume
- –
- Previous close
- $0.00210000
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$2.57m | -$3.09m | -$3.66m | -$3.38m |
| Net income | -$2.51m | -$3.01m | -$3.32m | -$3.32m |
News
8 latest- Stock Indices Plunge Amid Broad Market WeaknessBarchart · 4 minutes ago
- PayPal Holdings, Inc. Appoints Claire Bramley as CFO and Brian J. Lee to Board Effective November 30, 2026Fintel · 11 minutes ago
- TDH Holdings, Inc. Reports First Half 2026 Financial ResultsFintel · 11 minutes ago
- IES Holdings Reports Fiscal 2026 Fourth Quarter and Full Year ResultsFintel · 11 minutes ago
- Bitwise CIO Predicts Hyperliquid Could Become "the Next Amazon." Here's Why He's Right.The Motley Fool · 22 minutes ago
- FirstEnergy Corp. Increases 2026-2030 Capital Investment Plan to $38 billionFintel · 23 minutes ago
- Rocket Lab Missed on Q3 Earnings -- and That's Great NewsThe Motley Fool · 25 minutes ago
- NextCure, Inc. Receives Nasdaq Non-Compliance Notice on November 16, 2026Fintel · 32 minutes ago
The company
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on developing innovative therapies to restore balance to the body's inflammatory response. Through its proprietary Gemini therapeutic platform, Revelation is pursuing a differentiated approach to treating diseases driven by excessive or dysregulated inflammation. The Company's lead program targets acute kidney injury, a serious condition with significant unmet medical need and limited treatment options. Revelation believes Gemini's multimodal mechanism of action has the potential to support improved healing and recovery across a broad range of acute and chronic inflammatory diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- revbiosciences.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.